As shown in Figure 4, the results indicated that 9 of 13 members of the LSM family were significantly associated with poor OS of GC patients undergoing 5-FU based chemotherapy, such as LSM2 (HR = 1.52, p for trend = 0.019), LSM3 (HR = 1.57, p for trend = 0.01), LSM4 (HR = 1.75, p for trend = 0.0024), LSM5 (HR = 1.56, p for trend = 0.012), LSM6 (HR = 1.48, p for trend = 0.043), LSM7 (HR = 1.59, p for trend = 0.017), LSM8 (HR = 1.47, p for trend = 0.032), LSM11(HR = 3.23, p for trend = 0.019), and LSM14A (HR= 1.9, p for trend = 0.00026). This evidence concerns the gene LSM3 and gastric cancer.